Drug intelligence / Profile preview

Altebrel

Development stage: Phase 1
Lead developer: Aryogen Biopharma
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Altebrel is a biosimilar version of etanercept developed by AryoGen Pharmed as a recombinant dimeric fusion protein comprising the extracellular domain of the human p75 tumor necrosis factor (TNF) receptor linked to the Fc portion of human IgG1. It functions as a soluble TNF receptor that binds and neutralizes TNF-α (and TNF-β), thereby inhibiting downstream inflammatory signaling in immune-mediated diseases. Produced in Chinese hamster ovary (CHO) cells using recombinant DNA technology, Altebrel is approved in Iran for subcutaneous treatment of rheumatoid arthritis, ankylosing spondylitis/axial spondyloarthritis, psoriatic arthritis, plaque psoriasis, juvenile idiopathic arthritis, and related TNF-driven inflammatory disorders, with dosing regimens mirroring those of reference etanercept.

Brand names: Altebrel
Other names: Etanercept biosimilar (AryoGen)

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Altebrel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Altebrel.

Explore the full profile